Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary

March 17, 2026

NASDAQ US Health Care Pharmaceuticals earnings 44 min

Earnings Call Speaker Segments

Jennifer Good

executive
#1

Good afternoon, and thanks for taking part in our call about fourth quarter 2025 results and business progress. With me on this call today are my colleagues Dr. James Cassella, who serves as our Chief Development Officer; Farrell Simon, our Chief Commercial Officer; and David Hastings, our Chief Financial Officer. I'd like to welcome Dave to his first official earnings call with Trevi. We've already seen the impact of his experience within the company, and we consider ourselves quite lucky to have brought him onto our leadership team during this crucial period of execution and growth. So, welcome, Dave. I'll offer a few remarks about the business, and Dave will follow with some brief financial comments. After that, the team is glad to take whatever questions you have. 2025 represented a significant inflection point for Trevi's growth, powered by our positive data readouts from both the CORAL trial, which enrolled patients with idiopathic pulmonary fibrosis, or IPF related chronic cost, and the RIVER trial, which enrolled patients with refractory chronic cough, or RCC. Thanks to these data, we succeeded in raising capital, which positions us well for the next round of trials across each of our indications. That momentum has continued into the early part of this year, as we've been getting ready to launch the next set of clinical trials. This effort recently led to a positive end of Phase II meeting with the FDA concerning our IPF-related cough program. We believe the path forward for our registration trials is clear, and everyone at Trevi has been pushing hard to get our Phase III program underway. Let me update you on where things stand for each of our chronic crop indications. Starting with our lead indication, Haduvio for treating IPF-related chronic cough: at our recently held end of Phase II meeting with the FDA, we believe we achieved overall alignment regarding the plan for the remaining development program and the pathway to NDA. First, I'd like to share that the meeting was highly collaborative, and we appreciated the preparation and feedback from the FDA, particularly given all the changes happening at the agency. We had constructive dialogue about each of our questions and came away with a solid understanding of the path forward. During our interaction, we confirmed the primary endpoint using the objective cough monitor and discussed the proposed key secondary endpoints along with how these endpoints would be evaluated. Based on the FDA's input, the company intends to run 2 pivotal Phase III clinical trials and reached agreement on the remaining Phase I clinical studies needed to support an NDA submission. The company intends to run these 2 Phase III trials in parallel and remains on track to begin the clinical program. We plan to start the first trial during the second quarter of this year. That trial will be a global 52-week trial, with a primary efficacy endpoint following 24 weeks of fixed dosing. We've designed the trial to enroll roughly 300 patients. The second confirmatory Phase III study, which we anticipate kicking off during this year's second half, is likewise going to be global, with its primary efficacy endpoint measured at 12 weeks, and we estimate it will randomize about 130 patients. Apart from differing lengths for the primary efficacy endpoints and the number of subjects, the designs of these 2 studies are nearly the same. Those differences exist because the FDA wants a 24-week readout in at least 1 of the trials to back up durability of effect. Turning to how the trials wrap up, the 52-week study featuring the 24-week endpoint has sufficient power for every key secondary endpoint we'd want on the label and backs an adequate safety database. The other Phase III trial examines a 12-week endpoint to verify the primary efficacy results while also delivering added safety data across 12 weeks of dosing. IPF-related chronic cough represents a new indication for the FDA, and we think this pivotal program delivers strong safety and efficacy data for a possible NDA submission. Within the U.S., roughly 150,000 IPF patients exist, and 2/3 of them suffer uncontrolled chronic cough; such cough patients face a high unmet need, as no FDA-approved therapies are available. Given our distinct mechanism of action plus our established safety and tolerability profile, we believe our positioning is strong to potentially bring the first therapy for treating IPF-related chronic cough. A brief note as well on the remaining Phase I studies. All of them are standard label-enabling studies that we had already been planning within our development program, and they match what we submitted to the FDA in our briefing document. Jim can provide more color during Q&A should you be interested. After aligning with the FDA on our IPF-related chronic cough program, we now plan to submit a meeting request and protocol to the FDA seeking our non-IPF interstitial lung disease, or non-IPF ILD-related chronic cough program. We plan to propose an adaptive Phase IIb trial to confirm dose and powering assumptions before rolling into 1 pivotal Phase III trial for approval. Our plan is to file a supplemental NDA for this indication. We intend to hold this meeting in this year's third quarter, and should everything proceed as planned with the FDA, launch that trial by year-end. This population will cover non-IPF ILD patients who suffer from lung fibrosis and chronic cough. We estimate roughly 228,000 non-IPF ILD patients exist, with 50% to 60% experiencing uncontrolled cough. That more than doubles the market opportunity of IPF chronic cough, and these patients are mainly seen by the same pulmonologists as IPF patients; this keeps our clinical and commercial efforts efficient and create synergies. Lastly, for refractory chronic cough. We plan to run a Phase IIb parallel arm dose-ranging trial with 3 doses and placebo. We've got the protocol written and it's now going out to regulators, plus we've chosen the sites where this trial will run. From a scientific standpoint, this trial is quite interesting, since we're looking into whether the dosing for RCC patients turns out lower than, or similar to, the doses we're studying in the IPF chronic cough trial. Our plan is to get this trial started in Q2 of this year too, and we've built in a sample size reestimation readout once 50% of the patients have finished the trial; things have been really busy at Trevi as we get ready to kick off this next round of clinical trials. Jim and his team have put in tremendous effort to build on the key learnings and relationships we've already established, and also to grow our clinical footprint into the U.S. We're eager to get these trials underway and start enrolling patients. Before I wrap up, I want to mention that we're getting ready for 2 important meetings in the second quarter, and we hope to see a lot of you there. The first one is an in-person Investor and Analyst Day on May 7, running from 10:00 a.m. to 12:00 p.m., with an optional lunch afterward in New York City to talk through the company's clinical and commercial strategy. We'll be joined by KOLs from both IPF and RCC. At this event, we intend to lay out our clinical trials and time lines in greater detail, share recent commercial learnings that Farrell has been busy working on based on our recent data here from KOLs on their perspective, and I also plan to talk about our ongoing efforts to secure additional intellectual property; so it should be an informative event; we'll also webcast it live for those of you who can't be there in person. Second, we'll also have a strong presence at the American Thoracic Society, or ATS meeting this year, with all of our submissions accepted for either presentations or posters. We'll be sharing some new data from our various trials at this meeting. We're planning to hold an investor event at ATS, where Jim and Dr. Philip Malone, the lead investigator on our CORAL trial, will summarize and share the various data being presented at the conference. This meeting takes place in Orlando from May 17 to 19, with our ATS investor event happening on Monday, May 18. If you're planning to attend ATS, please get in touch with us, since we'd love to have you there; so in closing, Trevi is well positioned to execute against our plan of becoming the leader in chronic cough, providing therapy for these patients where there are not good options and in the process, creating meaningful value for our shareholders. I'll now hand things over to Dave for his remarks, and then we're happy to take your questions. Dave?

Dave Hastings

executive
#2

Thank you, Jennifer, and good afternoon to everyone. To start, I'd like to share how excited I am to be on my first earnings call since becoming Trevi's CFO. Before we get into the financial results, let me take a moment to explain what drew me to this position. This company has remarkable clinical data across indications where unmet medical need is high and the commercial opportunity is substantial. What's more, because these are specialty indications, we're able to launch them commercially in an effective way. On top of that, Trevi has demonstrated it can deploy capital efficiently while advancing its main clinical programs; and after getting to know the team, I came away confident in their capacity to deliver, and I'm eager for the chance to make a contribution. Now, on to our key financial metrics, which center on cash and what that runway supports. We closed 2025 with roughly $188 million across cash, cash equivalents and marketable securities, giving us an anticipated runway extending into 2028; that runway lets us deliver top line data from our key clinical trials. Those include our Phase IIb clinical trial in RCC, our Phase IIb clinical trial in non-IPF related chronic cough, and, importantly, top line data from our 12-week pivotal Phase III clinical trial in IPF-related chronic costs. So although our cash runway puts us in a solid position to hit key clinical milestones, it matters that Trevi always stays appropriately capitalized in light of the key inflection points and significant clinical trial data readouts that lie ahead; with that said, I'll hand the call back to the operator so we can begin Q&A. Operator?

Roanna Ruiz

analyst
#3

I've got a couple of things. I'd like to follow up on those Phase I trials still outstanding that you mentioned discussing with the FDA during the end meeting. Could you say a little more about which questions those are supposed to address, and how quickly do you figure you can get them finished in the near term?

Jim Cassella

executive
#4

Ron, it's Jim here. Appreciate the question. Essentially, these trials mostly serve to inform the label. To be specific, the FDA requested that we examine NeurodomaLast, now that it's a newly approved antifibrotic agent, to determine whether any drug-drug interaction exists with it; we'd already carried out that work with pirfenidone and tentative; so we were sort of anticipating that this one would be on its way. The purpose is to confirm there's no PK drug interaction capable of altering the PK levels of NeurodomaLast or the other way around, the PK of on <<inaudible>>. That covers the first one. Given that we'd just wrapped up those others, it was fairly expected. The second one concerned how our drug gets metabolized. Part of our metabolism happens through cytochrome P450 liver enzymes, more precisely, we're metabolized by Cytochromes P450, the 2C9 and 2C19 isoforms, and we'd intended to run an inhibitor study examining drugs that inhibit these enzymes to see whether there's an effect. Should it influence RPK, the FDA preferred to take things 1 step further and examine inducers of those enzymes. Once again, this is fairly routine, and we can inform physicians through the label about what occurs when we do it; what we'd also put forward, and which got accepted, were standard label-enabling studies covering renal impairment, hepatic impairment, food effect, and similar items; so we're in a good place there. I believe we have a solid understanding of what's needed from us on the path to the NDA; none of these are rate limiting at all; they're doable alongside the Phase III, and we'll carry them out as we proceed.

Roanna Ruiz

analyst
#5

Wonderful. That's useful. Now I have another question about non-IPF ILD, and about appearing before the FDA regarding that trial's design too. Are there particular design elements you're most eager to get aligned with the FDA on? And do you anticipate any questions, or points where you might need to have a longer discussion with the FDA? .

Jim Cassella

executive
#6

Yes, excellent question. What's great about where we are in terms of timing, I'd say, is that we're just coming off a very favorable end of Phase II meeting in IPF. And as you know, that's one type of ILD, interstitial lung disease. So we're essentially examining the other portion of that ILD population. So I'd say many of the takeaways from our end of Phase II meeting apply directly to what we're aiming to accomplish in non-IPF ILD. So all that we gained from the end of Phase II meeting regarding study design, regarding what the FDA examines when it comes to study duration, and even regarding our endpoints, will truly transfer over. So our goal with that meeting is essentially to familiarize them with the notion that we're focused on this other segment of the population. We're planning to pursue this through a Phase II, Phase III adaptive design, and as Jen said, the Phase II portion is really — this is a somewhat different population. There will be additional comorbidities tied to this non-IPF ILD population, so we're going to conduct some dose ranging during the Phase II portion. What the adaptive design is meant to do is let us select our doses, establish what our effect size is, examine the variability within this population, and then immediately bring that into the Phase III study. A data readout will occur in between those. So essentially, we're going to present that concept to them during the Type C meeting we intend to have with them.

Judah Frommer

analyst
#7

Well done on the advancement. Dave, welcome aboard. Perhaps starting with us regarding non-IPF ID. Did any discussion occur at the conclusion of Phase II concerning possibly incorporating a cohort within the pivotal study for IPF that might encompass non-IPF patients — if not, was your sense simply that it wasn't the appropriate design? Additionally, at the close of Phase II, could you provide any insight into the conversation about 1 study versus 2? I realize you'd consistently presumed 2 studies would be run here. Yet did any dialogue take place regarding that?

Jim Cassella

executive
#8

Right. Regarding non-IPF ILD — we — the IPF study serves as our primary program. It carries a quite unambiguous mandate; it represents a highly specific population; it's what we'd in fact referenced at the time of our IND submission; therefore we truly confined it to the IPS portion of the ILD population. The plan was for us to absorb the insights from that meeting and subsequently extend them to ILD. Consequently, no direct discussions on that took place. I'll have Jen weigh in regarding the latter point.

Jennifer Good

executive
#9

Yeah. Regarding the 1 versus 2, Judah, I believe feedback from the agency was positive and we had productive discussion with them during the meeting. There's currently, as you're aware, this kind of intermediate period where New England Journal articles are circulating that haven't yet made their way into FDA guidance. That situation, I think, creates some uncertainty at FDA about how to handle it, particularly in our case since this is a completely new indication — no chronic cough medication has ever received approval, and this would be the first one ever approved. So after our management team walked away from all the input we received, we concluded that the wisest course was to focus heavily on our lead indication and run a thorough study, so we wouldn't be vulnerable to any shifting perspectives in that area. It was ultimately a choice made by us as a company. We have substantial confidence in our ability to execute a successful trial, and these aren't large studies given the size of our drug's effect. So I'd characterize it as having flexibility, likely in either direction, and we chose to safeguard our lead program and proceed with 2 studies.

Judah Frommer

analyst
#10

Got it, that's clear. Now, one more thing about refractory chronic off. Sounds like you've got a strategy in place. I'm just wondering — whatever you learn from the P2X3 readout coming around the middle of the year, could that have any effect on the program?

Jennifer Good

executive
#11

Interesting question — that one ought to report in Q3. Clearly, it matters for patients. I believe our approach differs somewhat. We're targeting those who've failed treatment. The single piece of information I suspect Jim especially wants to see is what the placebo response looked like in their study. My guess is we're hoping it either succeeds or fails. I don't really think it changes anything about our efforts. We'll examine certain specifics of the trial. Whether all of that will be out by the third quarter, I'm not sure. It might arrive afterward, when they publish. Still, that's likely the most fascinating piece. Farrell, Jim — anything either of you would like to add? No.

Jim Cassella

executive
#12

No, I believe you've got that right.

Annabel Samimy

analyst
#13

Jaya here, filling in for Annabel. Nice work on the advances. Two things I wanted to ask. The first concerns how long the cash will last. It covers the Phase IIb trial in RCC, the Phase IIb P study, plus a 12-week IPCC readout. Does that also mean 24-week data include 4-week IPCC?

Dave Hastings

executive
#14

Yes, that's right; this carries us through, clearly, those important clinical milestones you just listed. And like I said, it matters that the company always stays properly capitalized, and we'll ensure funding is available for every one of our key clinical studies.

Jennifer Good

executive
#15

Dave, let me just throw in one historical point, since I've lived through this. What I believe shifted in a basic way coming out of our FDA meeting is that the agency is asking for 52 weeks of safety data from a controlled study. That forces us to keep the placebo group in place for 52 weeks, and as a result, we cannot report the 24-week endpoint until the whole thing finishes. So the requirement has moved somewhat. Had reporting at 24 weeks been possible, we would have been in a position to handle all of this. But since we now must keep that trial blinded and let it run to the very end, that is where some of the cap emerges. All that said, we are still working out precisely what the non-IPF ILD plan looks like and everything around it.

Jim Cassella

executive
#16

Right, and one more thing I want to mention — from a strategic standpoint, there are other ways we could put that cash to work, correct? That said, broadening the indications matters too, so that's the reason it's essential to launch the non-IPF ILD trial and generate results in that population.

Analyst

analyst
#17

My second question concerns the secondary endpoints within the IPF pivotal trial. What's your thinking there? Can you provide any color on that?

Jim Cassella

executive
#18

Absolutely. Jim here; in this program, obtaining the patient perspective matters a great deal to us. Objective cost monitor serves as the primary endpoint. Naturally, we employ that same measure in the CORAL study, yet additionally certain PROs we created and utilized in the CORAL study are going to be carried forward into the Phase III program. These chiefly center on how patients perceive cost frequency along with cost severity. We likewise obtained some quite intriguing data from the CORAL study concerning a possible effect on how subjects perceive breathlessness, so we're elevating that into a key secondary category given the very interesting findings we have there. And naturally, that measure matters greatly since patients truly do experience breathlessness following these coughing periods. Thus we consider that a highly important endpoint. It's something patients care about a great deal.

Jennifer Good

executive
#19

And Jim, that's one of the things we'll share at ATS.

Jim Cassella

executive
#20

Absolutely, we've got some really good figures to talk about when it comes to ATS. So I'll give you a bit of a preview.

Jennifer Good

executive
#21

Just a tiny amount more.

Analyst

analyst
#22

Nice work on such a strong year; Alexa here, filling in for Josh. Two brief questions, then. First off, when it comes to RCC, should we expect the label dose to match the one used in IPF? And should it differ, would you need to obtain extra IP for RCC dosing? Then my final question: are there plans to release RCC study data at some point during this year?

Jennifer Good

executive
#23

Sure. I'll handle that, Alexa, incidentally; regarding the label dose, that falls under what Jim has been tasked with. He'll head off and determine it. Looking at the crossover data, it seems that this entire effect shows up even at the smallest dose, quite soon. By 1 week, which was our first measurement point. There's likely a mechanistic explanation for why that could hold true — you require less drug; thus Jim will focus on the bottom portion of that dose range, plus the QD dose, which we intend to examine as well. So essentially we've instructed Jim that after he determines the right dose, we'll settle on the strategy; and should we ultimately land under the dose range we're currently using, extra IP will be needed, since some fresh formulation development will likely be required, and that work is in fact happening concurrently; so that's positive. Your other question — apologies, what was it again?

Analyst

analyst
#24

And do you intend to disclose results from the RCC trial?

Jennifer Good

executive
#25

Yeah. My apologies — I had merely jotted that down as a note, and afterward I lost track of its meaning. Right. So a sample size reestimation has been incorporated into our plan; we will not reach the conclusion of the RCC trial during this year. Our aim is to obtain that sample size reestimation readout before this year ends. So that is what we are hoping to accomplish. Once the study is formally started, we will provide guidance covering both — that milestone and the complete trial readout.

Serge Belanger

analyst
#26

Then a follow-up on the secondary endpoints. In your prepared remarks, I believe you said the bigger of the Phase III trials had statistical power for additional secondary endpoints that would go into the label. I'm just wondering whether that came as an FDA request or was it a strategic choice made by the company; and my second question is whether anything was discussed at the end of Phase II meeting about orphan drug designation, or is that a conversation held separately at a later point.

Jennifer Good

executive
#27

Jim, please go ahead.

Jim Cassella

executive
#28

I'll handle the opening portion of what you asked. So this is genuinely a matter of strategy, Serge, since what the FDA wants is controlled safety information covering 52 weeks. And given that this trial needs to go on for a longer period, the most efficient approach is for us to incorporate somewhat more into it. So clearly, that trial carries our 24-week primary endpoint using fixed dosing; and furthermore, since we are going to satisfy essentially our safety database obligation for 52 weeks on the drug, it proved simpler and more efficient to incorporate each of our key secondary endpoints. Keep in mind, as I noted, these are PROs; therefore they aren't as tidy as a signal; they carry somewhat greater variability, and somewhat more complexity toward the end of the trial. Incorporating all of that into the bigger Phase III trial was the most efficient route. And as for the second trial, it's essentially only confirmatory, featuring the 12-week endpoint. So the reason we proceeded that way truly comes down to efficiency and strategy.

Jennifer Good

executive
#29

Jim, our submission was our own idea rather than something the FDA required of us, correct? It's our proposed search, and they're on board with it. On the orphan drug matter, that's a fair thing to ask. An orphan drug application is something we intend to file this year. Like you've heard from me previously, my skepticism runs high about whether we can secure it, because although IPF qualifies as orphan, our focus is chronic P, which is generally regarded as 1 of the toughest chronic cost conditions. So their likely view will be that if it proves effective in IPF chronic cough, broader effectiveness is possible, and that's a question we want to answer. I'm not going to assume that. So we'll file, and we'll pose the question. Getting aligned with the FDA on our program first was our goal. Now that this is complete, we'll work to submit that application and get an answer to that question.

Ryan Deschner

analyst
#30

Since those major 2025 data readouts, have you gotten any feedback from patients or doctors pointing to greater familiarity with ADUVIO or your programs overall? That might help shape what we should expect for enrollment demand in the IPF chronic cough pivotal study. Then I have one more question.

Farrell Simon

executive
#31

Yes, Ryan, it's Farrell here. Over the summer we've put in a great deal of effort toward grasping how physicians behave and what mainly drives their preference. What rises to the top is the efficacy that came through. As a result, we've noticed physicians comprehend things better. We've also stayed quite busy engaging patient advocates both in the U.S. and outside it, so we know how to collaborate with them to serve patients more effectively; all of this connects smoothly with what Jim and his group are handling regarding awareness of clinical trials, and our team is focused on that too. Come May, at the Investor and Analyst Day, we'll share far more specifics about these insights.

Jennifer Good

executive
#32

Yeah. Like you're aware, Ryan, those trials mean we're headed into the U.S., and that's the cohort we've belonged to. And although receptions have been something we put on, plenty of those physicians turn up and push for it, and Jim plus me are gaining access there. On every one of our sites, response time has been solid, correct. So awareness is strong regarding our drug, our program, and the unmet need. The enrollment curves here, I'd say, have me enthusiastic. That, I believe, is within reach for us.

Farrell Simon

executive
#33

The response that we're getting from the sites over in the U.S. is quite enthusiastic. It's obvious that there's a great deal of interest in taking part in this trial for the drug.

Ryan Deschner

analyst
#34

Understood. So perhaps, just briefly, from a broader angle: do you expect any significant impact on your programs from the fairly recent FDA changes concerning credible mechanism, a greater focus on basin trial design, or even the recent staff turnover at the agency?

Jennifer Good

executive
#35

My answer would be no. What I'd say is, that's the great thing about this — Jim, feel free to jump in. But once the Phase II meeting wrapped up, we have a very clear route ahead, and that's the playbook we intend to carry out. Fortunately, I think the division — or rather the FDA division director — took a very active part in our meeting; so we know she's on board and firmly aligned with it. There's going to be considerable churn, or there is churn happening, in leadership positions — we don't fall under that branch. So I really don't see that having an effect on what we're doing, since we'll be keeping our heads down for the next 2 years, carrying out the plan that everyone agreed to; so I'm not sure, Jim, is there anything you'd like to add?

Jim Cassella

executive
#36

No. Beyond that — I believe you've captured it exactly; we're collaborating alongside the division. Their vision regarding what is required for a cough drug's approval came through very clearly, and they were quite excited about it. The Division Director spoke directly to the unmet need in this area and the toll it takes on patients. So that came across quite clearly. With this division, we have a clear line of sight regarding what must be accomplished. I think that's the key thing, and it's what we'll be working toward.

Brandon Folkes

analyst
#37

Congrats on all you've done. Maybe a few questions from my side, if that's okay. For moving into a Phase III trial in RCC after the Phase IIb, what's your thinking on timing? For the second indication to market, do you expect to make a call where, maybe following that Phase IIb in RCC, we could see more focus on non-IPF-ILD as the second indication to market, because of the commercial overlap, and also since you're likely to see off-label use in RCC?

Jennifer Good

executive
#38

That isn't the motivation. To start with, IPF is definitely the indication we're leading with, and I'd put ILD as number two, given how tightly linked those two are. That said, my view is that both non-IPF ILD and RCC would come through as sNDAs. That makes them fast follow-ons, meaning after an IPF approval, our goal would be to get both filings submitted in fairly close succession. Should a resource constraint ever come up around timing, ILD would get the nod, since those are the centers we'll be launching into, and it pairs very naturally with IPF. So when we sort through priorities on the inside, yes — it's IPF first, then ILD, which is practically family. When it comes to RCC, we're going to push forward quickly. There's a substantial need that isn't being met. In our view, the data for our drug in that setting looks strong. And once our IPF drug secures approval, there's nothing stopping us from having it ready. Our understanding is that just a single Phase III study will need to follow our IIb. So we'll be ready to maintain momentum.

Brandon Folkes

analyst
#39

Okay, thanks. For the next item, let's return to the Phase II IPF chronic cost. Can you give us a refresher, or walk us through your thinking, on what the placebo effect looks like when the duration stretches to 24 weeks?

Jim Cassella

executive
#40

Good question — I appreciate that. The CORAL study actually provided us with solid insight into how placebo behaves. Cough-related placebo response was roughly 17%. Among our subjects, that effect appeared during the initial two weeks or so. After that, for the active drug, the response stayed fairly consistent throughout. In that study, which was a bit on the smaller side, placebo was fluctuating around that level. Looking ahead, our thinking on it doesn't really change. It's something we still have to work out. The study should have enough statistical power to determine what the effect actually is, though at this stage it isn't truly unknown, and we'll get that answer from both the 12-week trial and the longer one. So, stay tuned, I'd say. Whatever shifts occur in that placebo response, we have adequate power to deal with them. For our primary endpoint — and for the key secondary endpoint too — the trial has more than 90% power. We've therefore included a certain cushion, the way you would when running a Phase III study. Still, my sense is that's something we'll all discover alongside each other.

Steven Jonathan

analyst
#41

I apologize if this was covered already and I overlooked it, but would you be able to share what the company is internally expecting regarding how quickly patients will be recruited and how long enrollment will take to finish in the Phase III IPSCO studies? Also, I have one more question after that.

Jim Cassella

executive
#42

Sure. Our CORAL study gives us strong, reliable data that lets us set some expectations for recruitment. Because of how large the first Phase III trial is — the bigger of the two — our expectation is that roughly a year will be needed to complete enrollment. We anticipate somewhere in the range of 80 to 100 sites. With those sorts of parameters, I believe the great majority of those centers are going to be located in the U.S., and in my view that gives us all these outstanding care centers where patient volumes are high. So for a trial of that kind, I'd say the 1-year expectation makes sense.

Analyst

analyst
#43

Alright, so if we figure on twelve months to get people enrolled, and after that you must track those patients across fifty-two weeks because of safety requirements, then when this might eventually secure approval, other IPF therapies could already be on the market — for instance, that United Therapeutics BMS admin product. Would filing then require us to run extra Phase I drug-drug interaction work?

Jim Cassella

executive
#44

That hinges on the timing of those approvals. In theory, we'd likely need a DDI study to confirm nothing happens to the PK. From what the mechanisms tell us, we can ask whether some form of drug-drug interaction should be anticipated — I believe timing will decide it. Once our enrollment period has wrapped up and the trial keeps running, then clearly no additional patients would have to be brought in. So timing, I think, is what matters, and we'll find out how it plays out. Still, conducting a Phase I DDI study isn't anything major. So I wouldn't view that as something blocking us.

William Wood

analyst
#45

I've got two things, and I'll begin with the first. Regarding your ILD trial, you said an adaptive design is planned. From what I recall, you've also said sarcoidosis would be excluded. Beyond that, what might the inclusion criteria look like? Should we anticipate coverage of every kind of ILD, perhaps even distinct pneumonia subtypes? Please walk us through how we ought to approach that. Then I have one more question.

Jim Cassella

executive
#46

Sure. Last year, we held a truly enlightening session with several KOLs, and the takeaway boils down to this: what every one of these individuals shares, despite possibly suffering from distinct comorbid conditions, is that each one suffers from interstitial lung disease to some degree. Each has some level of scarring, that scarring has the potential to worsen as time passes, and every one of them deals with cough, regardless of what proportion that represents. So the conclusion we reached was that no basket-style study would exist in which enrollment is determined by the diagnosis a person carries; instead, it must rest on the modified buses they present with and how much cost they bear. This approach strips things down to only what truly matters. Our belief is that the coughing is likely caused by the fibrosis in the first place. In that way, it addresses the root problems. That said, it doesn't mean comorbid conditions, CONMED, and similar factors won't need managing — those specifics will get sorted out later. Still, I'd say that captures what the trial is fundamentally about.

William Wood

analyst
#47

Understood. That tracks. Then, regarding how the FDA keeps shifting over time — I was wondering whether their perspective has changed at all when it comes to whether nalbuphine gets scheduled or stays unscheduled, and whether any new developments or readings on that have come up?

Jennifer Good

executive
#48

William, what I'd say is that we handed over our human abuse potential study. We handed over the data from our respiratory safety study, and we had a consult with controlled substance staff on the meeting. That meeting was quite constructive. I'd put it this way — my read is that the FDA is paying less attention to the molecule, since that one is already unscheduled, and more attention to our formulation plus whether anything distinctive about it might shift the profile on that front. What our data shows is that it doesn't. Jim did a really strong job pulling a cut around the different terms they use. When they get to the end of the study, there's simply not much to find. So I've been on this ride since the very start. And what I'd tell you is that my conviction just keeps getting stronger that this drug will remain on schedule. So there's nothing at the close of Phase II that would alter that. I'd describe the overall tenor as very relaxed on that point, with clear guidance regarding what interests them — which, frankly, centered more on dependence than on addiction. So I'm not sure, Jim, is there anything you'd like to add?

Jim Cassella

executive
#49

Right. No, though you raise a valid point. My sense is we told them to assume we'd figure out how to bring the data together in support of the combination when the NDA comes around; so obviously there are really solid day sets that have to be produced under VA and CSS direction, where those groups issue the terms for adverse events tied to these abuse-related terms. Yet, as Jen mentioned, quite a bit of discussion—or rather substantive discussion—took place regarding whether physical dependence followed by withdrawal can be observed. As a reference point, that falls under labeling rather than scheduling; so once more, there are 2 separate elements here that draw their interest. So it isn't that we anticipate seeing any of that, but it would be a labeling matter rather than a scheduling one.

Kaveri Pohlman

analyst
#50

Christian here, sitting in for Kaveri today. So you brought up that the Phase III IPF safety dataset covering one year might begin to give us insight into matters such as neo, exacerbations, hospitalizations, and possibly even how lung function trends evolve over time. Would any of those count as prespecified analyses, and which data points would genuinely alter your thinking regarding the label or the launch strategy?

Jim Cassella

executive
#51

Yes. There are many items we intend to monitor. Our approval request centers on cough. That, I believe, comes before everything else. We must have that label supported. One point we raised earlier is that cost patients genuinely worry about shortness of breath. Because of that, we are elevating breathlessness to the key secondary endpoint. That is plainly connected, and we will plainly be gathering data tied to those other matters you just mentioned. So we run FECs, we run other assessments, and we will examine hospitalizations. These patients are living with their disease, which is a terminal condition. So we will also be following those things across the year.

Analyst

analyst
#52

Understood — I appreciate that context, and I have just 1 additional question about the Phase III IPF population. In the past, you said you wanted that population to reflect real-world conditions as closely as possible, and that it would resemble the Phase IIb population while involving certain broadening efforts. Would you be able to discuss which segments of the patient population you are deliberately expanding into, compared with the Phase II CORO study?

Jim Cassella

executive
#53

There is considerable continuity from the CORAL study. For preparing us for this, CORAL was truly an excellent study, both for dose ranging and for gaining insight into the patient population. As a result, we are expanding things and making them as real-world as we can, which is plainly what the FDA is seeking. Some patients will be receiving background antifibrotic medications. That held true in CORAL and will hold true in this case. We have no cough count requirement for entering the trial. That held true in Coral. It holds true in this case. In fact, the FDA noted that no one anticipates finding cough monitors inside doctors' offices when patients visit. We do have additional data coming at ATS that examines minimum cough levels, and an arbitrary cutoff existed at roughly 10% cost per hour. There was a degree of concern about possibly capping those. We will cap the number of costs entering below 10 cost per hour. That emerged from the CORAL study. So we are learning from the CORAL study, yet the population is really very similar to that study.

Jennifer Good

executive
#54

Thanks for being here on today's call. I realize that for every one of you, earnings season is wrapping up right about now, so you must be worn out; we're eager to walk you through the progress we keep making in the second quarter, as we kick off clinical trials, and also at our Investor and Analyst Day in May, and at ATS. Thank you.

Operator

operator
#55

Thanks. That wraps up the conference call for today. We appreciate your participation. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.